Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes.
Lundkvist P, Sjöström CD, Amini S, Pereira MJ, Johnsson E, Eriksson JW. Lundkvist P, et al. Among authors: sjostrom cd. Diabetes Obes Metab. 2017 Jan;19(1):49-60. doi: 10.1111/dom.12779. Epub 2016 Sep 26. Diabetes Obes Metab. 2017. PMID: 27550386 Free PMC article. Clinical Trial.
Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
Lundkvist P, Pereira MJ, Katsogiannos P, Sjöström CD, Johnsson E, Eriksson JW. Lundkvist P, et al. Among authors: sjostrom cd. Diabetes Obes Metab. 2017 Sep;19(9):1276-1288. doi: 10.1111/dom.12954. Epub 2017 May 31. Diabetes Obes Metab. 2017. PMID: 28345814 Free PMC article. Clinical Trial.
A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss.
Pereira MJ, Lundkvist P, Kamble PG, Lau J, Martins JG, Sjöström CD, Schnecke V, Walentinsson A, Johnsson E, Eriksson JW. Pereira MJ, et al. Among authors: sjostrom cd. Diabetes Ther. 2018 Aug;9(4):1511-1532. doi: 10.1007/s13300-018-0449-6. Epub 2018 Jun 13. Diabetes Ther. 2018. PMID: 29949016 Free PMC article.
Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials.
van der Aart-van der Beek AB, van Raalte DH, Guja C, Hoogenberg K, Suchower LJ, Hardy E, Sjöström CD, Heerspink HJL. van der Aart-van der Beek AB, et al. Among authors: sjostrom cd. Diabetes Obes Metab. 2020 Sep;22(9):1556-1566. doi: 10.1111/dom.14067. Epub 2020 May 29. Diabetes Obes Metab. 2020. PMID: 32329160 Free PMC article. Clinical Trial.
Once-Weekly Exenatide in Youth With Type 2 Diabetes.
Tamborlane WV, Bishai R, Geller D, Shehadeh N, Al-Abdulrazzaq D, Vazquez EM, Karoly E, Troja T, Doehring O, Carter D, Monyak J, Sjöström CD. Tamborlane WV, et al. Among authors: sjostrom cd. Diabetes Care. 2022 Aug 1;45(8):1833-1840. doi: 10.2337/dc21-2275. Diabetes Care. 2022. PMID: 35679098 Free PMC article. Clinical Trial.
Combination Treatment with Verinurad and Allopurinol in CKD: A Randomized Placebo and Active Controlled Trial.
Heerspink HJL, Stack AG, Terkeltaub R, Jongs N, Inker LA, Bjursell M, Maklad N, Perl S, Eklund O, Rikte T, Sjöström CD, Perkovic V; SAPPHIRE Investigators. Heerspink HJL, et al. Among authors: sjostrom cd. J Am Soc Nephrol. 2024 May 1;35(5):594-606. doi: 10.1681/ASN.0000000000000326. Epub 2024 Feb 20. J Am Soc Nephrol. 2024. PMID: 38564654 Clinical Trial.
86 results